HORMONE REPLACEMENT AND RISK OF UTERINE FIBROID GROWTH

描述：(改编自申请人摘要)。子宫病 子宫肌瘤是一种常见的重大公共卫生问题，影响妇女。 所有年龄、种族背景和社会经济水平。当女人有了 子宫肌瘤到达围绝经期或绝经期后，它们面临着 令人不安的治疗困境。如果它们想要保存子宫，它们 通过服用激素替代疗法来承担导致子宫肌瘤生长的未知风险。另一方面 另一方面，使用HRT的好处是巨大的，特别是对 患心血管疾病或骨质疏松症的风险。几乎没有什么，如果 任何，检查使用HRT对子宫肌瘤增殖的影响的研究 以及子宫肌瘤患者的生长情况。建议的随机化、 对照、双盲临床试验将调查 一种常用的小剂量、持续性雌激素-孕激素替代疗法 方案刺激黑人和白人中的肌瘤生长和增殖 绝经后子宫肌瘤患者。将进行超声波评估 300名绝经后子宫肌瘤患者在基线、6个月、12个月和24个月时， 这将允许检查肌瘤生长的程度 发生了什么，如果是这样的话，增长是继续还是停滞。达到的程度 这种HRT方案影响的是与更年期相关的症状，与肌瘤相关的 还将检查症状和生活质量。风险-收益分析 将在考虑子宫和非子宫风险的情况下进行 和好处，基于本研究的结果和对其他 学习。这项研究的结果将对 越来越多的肌瘤患者进入绝经期并 治疗这些病人的临床医生。

DESCRIPTION: (Adapted from Applicant's Abstract). The disease of uterine fibroids is a common and significant public health problem, affecting women of all ages, racial backgrounds and socioeconomic levels. When women with fibroids reach the perimenopausal or postmenopausal periods, they face a troubling treatment dilemma. If they wish to preserve their uterus, they take an unknown risk of causing fibroid growth by taking HRT. On the other hand, the benefits of using HRT are substantial, particularly for women at risk for cardiovascular disease or osteoporosis. There are been little, if any, research done to examine the effect of HRT use on fibroid proliferation and growth among uterine fibroid patients. The proposed randomized, controlled, double-blinded clinical trial will investigate the extent to which a commonly prescribed low dose, continuous estrogen-progestin HRT regimen stimulates fibroid growth and proliferation among black and white postmenopausal fibroid patients. Ultrasound assessments will be conducted for 300 postmenopausal fibroid patients at baseline, 6, 12 and 24 months, which will allow an examination of the extent to which fibroid growth occurs, and if so, whether growth continues or plateaus. The extent to which this HRT regimen affects menopause-related symptoms, fibroid-related symptoms and quality of life will also be examined. A risk-benefit analysis will be conducted, taking into account both uterine and non-uterine risks and benefits, based on the results of this study and reviews of other studies. The results of this study will be of significant value to a growing body of fibroid patients reaching the menopause and to the clinicians who treat these patients.